Courtney M Lattimore1, Max O Meneveau2, Gina R Petroni3, Nikole E Varhegyi3, Gabriella C Squeo2, Timothy N Showalter4, Shayna L Showalter5. 1. Department of Surgery, University of Virginia Health System, Charlottesville, VA. Electronic address: cml4wh@virginia.edu. 2. Department of Surgery, University of Virginia Health System, Charlottesville, VA. 3. Division of Translational Research & Applied Statistics, Department of Public Health Sciences, University of Virginia Health System, Charlottesville, VA. 4. Department of Radiation Oncology, University of Virginia Health System, VA 22908. 5. Department of Surgery, University of Virginia Health System, Charlottesville, VA. Electronic address: snl2t@virginia.edu.
Abstract
PURPOSE: To investigate patient-perceived quality of life (QOL) among patients treated with a novel form of breast intraoperative radiation therapy (PB-IORT). METHODS AND MATERIALS: Patients treated with PB-IORT as part of a phase II clinical trial from 2013 to 2020 were identified. Patients were given the European Organization for Research and Treatment of Cancer (EORTC) core 30-item Quality of Life Questionnaire (QLQ-C30) encompassing global health, functionality, and symptomatology at baseline, 1-month, 6-months, 12-months, and 24-months after PB-IORT. Scores were on a 100-point scale with change greater than 10 considered clinically significant. Scores at interval follow-up were compared to baseline using repeated measure modeling with an unstructured covariance matrix. RESULTS: The cohort consisted of 303 patients, a majority of which were White (84.2%) with a median age of 64 years (IQR: 52, 76). One month after PB-IORT, a decline from baseline in physical (-2.5, 95% CI: -4.4 - -0.55, p = 0.01), role (-7.6, 95% CI: -11.7 - -3.5, p < 0.001), and social functioning (-3.0, 95% CI: -5.5 - -0.42, p = 0.02) were observed, which correlated with increased fatigue (8.4, 95% CI: 5.5-11.3, p < 0.001). At 6 months, nearly all QOL measures returned to baseline or improved. There were no statistically or clinically significant differences from baseline in overall global health. All functional and symptom scale differences were less than 10, indicating minimal clinical significance. CONCLUSIONS: PB-IORT has minimal negative impact on QOL, further supporting this patient-centered treatment approach for early-stage breast cancer.
PURPOSE: To investigate patient-perceived quality of life (QOL) among patients treated with a novel form of breast intraoperative radiation therapy (PB-IORT). METHODS AND MATERIALS: Patients treated with PB-IORT as part of a phase II clinical trial from 2013 to 2020 were identified. Patients were given the European Organization for Research and Treatment of Cancer (EORTC) core 30-item Quality of Life Questionnaire (QLQ-C30) encompassing global health, functionality, and symptomatology at baseline, 1-month, 6-months, 12-months, and 24-months after PB-IORT. Scores were on a 100-point scale with change greater than 10 considered clinically significant. Scores at interval follow-up were compared to baseline using repeated measure modeling with an unstructured covariance matrix. RESULTS: The cohort consisted of 303 patients, a majority of which were White (84.2%) with a median age of 64 years (IQR: 52, 76). One month after PB-IORT, a decline from baseline in physical (-2.5, 95% CI: -4.4 - -0.55, p = 0.01), role (-7.6, 95% CI: -11.7 - -3.5, p < 0.001), and social functioning (-3.0, 95% CI: -5.5 - -0.42, p = 0.02) were observed, which correlated with increased fatigue (8.4, 95% CI: 5.5-11.3, p < 0.001). At 6 months, nearly all QOL measures returned to baseline or improved. There were no statistically or clinically significant differences from baseline in overall global health. All functional and symptom scale differences were less than 10, indicating minimal clinical significance. CONCLUSIONS: PB-IORT has minimal negative impact on QOL, further supporting this patient-centered treatment approach for early-stage breast cancer.
Authors: Adam A Garsa; Daniel J Ferraro; Todd A DeWees; Teresa L Deshields; Julie A Margenthaler; Amy E Cyr; Michael Naughton; Rebecca Aft; William E Gillanders; Timothy Eberlein; Melissa A Matesa; Laura L Ochoa; Imran Zoberi Journal: Int J Radiat Oncol Biol Phys Date: 2013-10-22 Impact factor: 7.038
Authors: Neil K Taunk; Bruce G Haffty; Sining Chen; Atif J Khan; Carl Nelson; Dorothy Pierce; Sharad Goyal Journal: Cancer Date: 2011-03-01 Impact factor: 6.860
Authors: Sunil W Dutta; J Hunter Mehaffey; Jason C Sanders; Max O Meneveau; Courtney Lattimore; Bruce Libby; David R Brenin; Anneke T Schroen; Einsley M Janowski; Carl Lynch; Donna J Lash; Timothy N Showalter; Shayna L Showalter Journal: Brachytherapy Date: 2019-03-04 Impact factor: 2.362
Authors: Bernard Fisher; Stewart Anderson; John Bryant; Richard G Margolese; Melvin Deutsch; Edwin R Fisher; Jong-Hyeon Jeong; Norman Wolmark Journal: N Engl J Med Date: 2002-10-17 Impact factor: 91.245
Authors: Taryn E Hassinger; Timothy N Showalter; Anneke T Schroen; David R Brenin; Adam C Berger; Bruce Libby; Shayna L Showalter Journal: J Med Imaging Radiat Oncol Date: 2018-08-13 Impact factor: 1.735
Authors: Grit Welzel; Angela Boch; Elena Sperk; Frank Hofmann; Uta Kraus-Tiefenbacher; Axel Gerhardt; Marc Suetterlin; Frederik Wenz Journal: Radiat Oncol Date: 2013-01-07 Impact factor: 3.481